Physician profile
Alfred Castillo
NPI 1194098954
$3,268.52
in general payments reported to CMS, 2019-2025
31 companies · $610 in 2025
The $610 reported for 2025 was more than what 86% of Sports Medicine (Physical Medicine & Rehabilitation) providers received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $130 · 2020: $95.09 · 2021: $50.65 · 2022: $463 · 2023: $960 · 2024: $959 · 2025: $610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,529.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,529.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $696.73 | 2022-2025 | Intracept |
| Relievant Medsystems, INC. | $686.99 | 2022-2023 | Intracept |
| Nevro Corp. | $308.39 | 2022-2024 | Senza |
| Abbvie INC. | $283.14 | 2022-2025 | Qulipta, Botox |
| Ferring Pharmaceuticals INC. | $168.00 | 2023-2025 | Euflexxa |
| Endo Pharmaceuticals INC. | $153.43 | 2019-2021 | |
| Vertos Medical, INC. | $131.95 | 2023 | Mild Device Kit |
| Xeris Pharmaceuticals, INC. | $91.64 | 2024-2025 | Recorlev, Gvoke Hypopen |
| Saluda Medical Americas, INC. | $72.75 | 2025 | Evoke |
| Novo Nordisk INC | $66.25 | 2025 | Wegovy |
| Abbott Laboratories | $55.40 | 2024-2025 | Proclaim |
| Recordati_rare_diseases_inc. | $49.76 | 2025 | Isturisa |
| Medtronic, INC. | $47.59 | 2023-2024 | Vanta Adaptivestim, Intellis Adaptivestim |
| Verity Pharmaceuticals INC. | $43.49 | 2024-2025 | Tlando |
| Depuy Synthes Sales INC. | $43.40 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $35.35 | 2021-2022 | |
| Painteq LLC | $34.01 | 2024 | Painteq |
| Ascensia Diabetes Care US INC. | $28.41 | 2025 | |
| Bioventus LLC | $26.20 | 2023 | Durolane |
| Amneal Pharmaceuticals LLC | $24.64 | 2025 | Unithroid |
| Integra Lifesciences Corporation | $24.20 | 2019 | |
| Collegium Pharmaceutical, INC. | $22.14 | 2021 | |
| Tandem Diabetes Care, INC. | $21.03 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Dexcom, INC. | $20.37 | 2025 | Dexcom G6 Transmitter |
| Horizon Therapeutics Plc | $20.31 | 2022 | |
| Insulet Corporation | $20.03 | 2024 | Omnipod |
| Acella Pharmaceuticals, LLC | $19.29 | 2025 | NP Thyroid 60 |
| Tonix Medicines, INC. | $19.09 | 2025 | Tonmya |
| Sanofi-Aventis U.S. LLC | $19.08 | 2019 | |
| Globus Medical, INC. | $18.70 | 2025 | Senza |
| Valinor Pharma, LLC | $16.76 | 2024 | Movantik |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alfred Castillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.